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Elimination of Various Subpopulations 
of Macrophages and the Development of 
Multiple-Organ Dysfunction Syndrome in Mice
Grard A. P. Nieuwenhuijzen, MD; Maarten F. C. M. Knapen, MD; Thijs Hendriks, PhD; 
Nico van Rooijen, PhD; R. Jan A. Goris, MD, PhD
Objective: To evaluate the role of specific macrophage 
subpopulations in the development of zymosan- 
induced multiple-organ dysfunction syndrome by selec­
tive elimination of liver, splenic, alveolar, and perito­
neal macrophages.
Design: Randomized animal trial.
Setting: Central animal laboratory at the University Hos­
pital Nijmegen, Nijmegen, the Netherlands.
Animals: Male C57B1/6 mice.
in terventions: Elimination of macrophages was ac­
complished by administration of multilamellar lipo­
somes that contained dichloromethylene bisphospho- 
nate (C12MBP). Intravenous, in tratracheal, and 
intraperitoneal administrations induced an elimination 
of liver and splenic, alveolar, and peritoneal and omen­
tal macrophages, respectively. Zymosan (1 mg/g) was in­
jected intraperitoneally at day 0. The liposomes that con­
tained C12MBP were administered before and after 
zymosan challenge. At day 12, all surviving mice were 
killed.
Main Outcome M easures: The body weights, tempera­
tures, and mortality rates of the mice were monitored daily.
Relative organ weights (ROWs) were calculated from the 
lungs, liver, spleen, and kidneys after the mice were killed.
Results: The liposomes that contained C12MBP, admin­
istered intravenously before or after zymosan challenge, 
did not induce significant changes in the body weight, 
temperature, or mortality rate. The ROW of the liver was 
significantly decreased in both treatment groups. Elimi­
nation of liver and splenic macrophages after zymosan 
challenge induced an increased ROW of the lung and a 
decreased ROW of the liver. The liposomes that con­
tained C12MBP, administered intratracheally before zy­
mosan challenge, completely prevented deaths. The body 
weights, temperatures, and ROWs of the mice were not 
changed. The liposomes that contained C12MBP, admin­
istered intraperitoneally, did not change the body weight, 
temperature, or ROW. The liposomes that contained 
C12MBP, administered intraperitoneally before zymo­
san challenge, increased the mortality from 50% to 90%.
Conclusions: These data show that the elimination of spe­
cific macrophage subpopulations and the elimination on 
specific time points in this model had differential effects, 
indicating a differential role of specific macrophage sub­
populations, either protective or detrimental, in the devel­
opment of multiple-organ dysfunction syndrome.
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N NORMAL host-defense media- macrophages that could induce a general- 
nisms, an inflammatory response ized dysregulated excessive inflammatory re-
is ideologically beneficial and is 
meant to protect the host against 
injurious events. n ; con-
sponse, leading to the development of SIRS, 
ARDS, or MODS.4'6 This hypothesis is sup­
ported by various observations. First, ad- 
trary, in pathological conditions (eg, the sys- ministration of macrophage-derived cyto- 
temic inflammatory response syndrome kines to healthy volunteers produces a 
[SIRS], the adult respiratory distress syn­
drome [ARDS], and the multiple-organ dys­
function syndrome [MODS]), an exces­
sive generalized inflammatory response may
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rophages play a pivotal role in normal host- 
defense mechanisms because of their anti­
microbial phagocytic activity, antigen- 
presenting capacity, and regulation of the 
inflammatory response by their secretion of 
various imimmoregulatory substances.5 
However, evidence has been accumulating terleukin-1,, and neopterin) with a positive 
with regard to an excessive activation of correlation of elevated levels with the sub-
ARDS, and MODS, as demonstrated by in­
creased levels of macrophage-derived prod­
ucts (eg, tumor necrosis factor [TNF], in-
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MATERIALS AND METHODS 86 mg of phosphatidylcholine (Lipoicl GmbH, Ludwig- shafen, Germany) and 8 mg of cholesterol (Sigma Chemi-
ANIMALS ca* were dissolved in 10 mL of chloroform, and a lipid
film was produced by low-vacuum rotaiy evaporation. Sub- 
Inbred, specific pathogen-free, male C57B1/6 mice (Charles sequently, 10 mL of the C12MBP solution was added, and
Rivers, Wiga, Germany) (age range, 6-8 weeks) were adapted 
to handling in their cages for 7 days prior to the start of the
the suspension was left at room temperature for 2 hours, 
sonicated for 3 minutes at 20°C, and left for 2 hours at 37°C.
actual experiment. Throughout the experiment, all mice had The liposome suspension was then diluted in 100 mL of 
free access to water that was acidified with hydrochloric acid PBS, centrifuged at 100 OOOg for 30 minutes to remove free
(to pH 3) and to standard mice laboratory chow (RMH-GS 
pellets [irradiated at 10 kGy], Hope Farms, Woerden, the 
Netherlands). The room temperature was kept constant at 
21°C, and a 12-liour lighting cycle was maintained. The ex­
periments were approved by the Animal Ethics Committee 
of the Medical Faculty of the University of Nijmegen, Nij­
megen, the Netherlands.
C12MBP, and resuspended in 4 mL of PBS.
ELIMINATION OF MACROPHAGE 
SUBPOPULATIONS
ZYMOSAN
Elimination of Kupffer cells and splenic macrophages was 
achieved by an intravenous (IV) injection of 200 |xL of li­
posomes that contained C12MBP in the tail vein; this method 
has been demonstrated previously to achieve an elimina­
tion of these macrophages within 2 days.22 Alveolar mac-
ZymosanA (Sigma Chemical Co, St Louis, Mo), sterilized by rophages were eliminated by administering Cl2MBP~ 
use of 7-irradiation (5 kGy), was suspended (25 mg/mL) by containing liposomes intratracheally (IT).27 The mice were
high-frequency vibration in liquid paraffin (60-80 mPa, Eu­
ropean Pharmacopoeia PA.S.68.81 CP846021). The suspen­
sion was sterilized by incubation in a water bath at 100° C for 
80 minutes. One day before use, the suspension was heated hydrochloride (Rompun, Bayer, Leverkusen, Germany), and
fixed in an upright position under total anesthesia with 30 
|xL of a mixture (ratio, 4:3:7) of ketamine hydrochloride 
(100 mg/mL) (A.U.V., Cuijk, the Netherlands), xylazine
to 40°C and dispersed by high-frequency vibration for 15 min­
utes. Sterility was confirmed by culture on a blood agar me­
dium. The zymosan suspension was administered IP in a dose 
of 1 mg/g of body weight.
saline that was injected intramuscularly. Using a nylon tube 
(diameter, 0.46 mm) that was connected to a 1-mL sy­
ringe fixed in a micromanipulator, 100 |xL of the C12MBP- 
containing liposome suspension was administered through 
the glottis into the trachea. It has been demonstrated by 
this method that alveolar, but not interstitial, macro­
phages are eliminated within 3 to 5 hours.27 Elimination 
of peritoneal macrophages was accomplished by adminis- 
Multilamellar liposomes were composed of phosphatidyl- tering 100 |xL of Cl2MBP-containing liposomes IP, 2 times 
choline and cholesterol (molar ratio, 6:1) and contained successively.28 The latter method has been demonstrated
PREPARATION OF Cl2MBP-CONTAINING 
LIPOSOMES
C12MBP dissolved in phosphate-buffered saline (PBS [0.25 
g/mL]). They were prepared as described earlier.22 In brief,
to eliminate peritoneal, omental, and, to a lesser extent, liver 
and splenic macrophages within 4 days.28
sequent mortality rate.9,10 Finally, anticytokine strategies 
have attenuated or prevented the development of SIRS and 
subsequent MODS in various experimental models.11'13
Several studies have been ascribed a special patho­
physiological role to specific macrophage subpopula­
tions (eg, alveolar macrophages,14,15 Kupffer cells,16,17 
splenic macrophages,18,19 and peritoneal macro­
phages20,21) in these syndromes.
An alternative approach to study the respective causal 
role of macrophage subpopulations in the pathogenesis 
of MODS is by investigating the effects of selective elimi­
nation of these cells. For this purpose, we used the “li­
posome-mediated macrophage suicide technique.”22 In 
this approach, dichloromethylene bisphosphonate 
(C12MBP or clodronate) is selectively delivered intracel- 
lularly to macrophages by a liposome carrier; this re­
sults in a destruction of the cell. Other cells are not struc­
turally or functionally affected by this technique.23 By 
varying the route of administra tion, liposomes can be tar­
geted to eliminate macrophages in specific tissues.22
We have applied this technique in the zymosan- 
inducecl generalized inflammation model. In rodents, in- 
traperitoneal (IP) challenge with zymosan, a particulate
cell wall product of the yeast Sa.ccha.romy ces cerevisiae, in­
duces a typical triphasic illness with an early hyperdynamic 
response with concurrent bacterial translocation from the 
gut and, after a recovery phase, a late bacteria-independent 
hypodynamic MODS-like phase with a generalized inflam­
matory response and organ dysfunction.24,25
Recently, we have shown that elimination of liver 
and splenic macrophages can abrogate the early hyper­
dynamic response in this model, despite an increased bac­
terial translocation.26 The purpose of the present study 
is to determine the role of specific macrophage subpopu­
lations (ie, liver, spleen, alveolar, or peritoneal macro­
phages) in the development of MODS by studying the 
consequences of selective elimination of those macro­
phage subpopulations, either prior to or after the chal­
lenge with zymosan, for the clinical syndrome and or­
gan damage in the late phase of this model.
RESULTS
Elimination of liver and splenic macrophages was con­
firmed by the absence of acid phosphatase activity of liver 
and splenic tissue (Figure 1) in the mice that were treated.
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I‘Oi each route ol liposome administration, verifica- groups received liposomes either 2 days before or 4 days
tion of macrophage elimination was performed on 3 ani- after zymosan challenge. The effects of IT liposome ad-
s were compared with those for un- ministration were studied, in 3 groups of 20 mice each. The
treated mice. Elimination of macrophages in the liver and experimental groups received liposomes either 3 days be-
spleen was verified by analyzing acid phosphatase activity fore or 4 days after zymosan challenge. Three groups of simi-
in 8-(xm cryostat tissue sections of liver and spleen 2 days lar size were used to examine the effects of IP liposome ad-
after IV injection of CljMBP-containing liposomes. Acid ministration, for which the experimental groups received
phosphatase activity was demonstrated by incubation with liposomes either both 4 days and 1 day before or 1 day and
1% naphthol-AS-BI—phosphate and 4% hexazotized para- 4 days after zymosan challenge.
rosaniline for 30 minutes at 37°C. Elimination of alveolar In all mice, body weight and rectal temperature were
macrophages was verified by quantification of macro- measured daily. The clinical condition with possible symp- 
phages in the alveolar lavage fluid at 2 days after IT ad- toms such as loss of hemorrhagic fluid from the nose, con- 
niinistration of Cl MBP-containing liposomes. After the junctiva, and mouth, lethargy, anorexia, hyperventila- 
lungs were dissected free, alveolar lavage was performed 3 tion, ruffled fur and loss of liquid stools, and mortality rate 
times with 1 mL of PBS that contained 0.38% citrate. After were monitored. On day 12, all surviving mice were bled 
staining with trypan blue, cells were counted using a he- and killed by cervical dislocation; the lungs with the tra- 
mocytome ter chamber (Burker counter, Tamson Co, Zoe- chea, kidneys, liver, and spleen were dissected free and 
termcer, the Netherlands). Cytospin preparations con- weighed. Relative organ weights (ROWs) were calculated 
firmed that more than 95% of the alveolar cells were by the following formula: ROW= (organ weight/body 
macrophages. Elimination of the peritoneal macrophages weight) X100%. 
was verified by quantification of macrophages in the peri­
toneal lavage fluid. The liposomes that contained C12MBP STATISTICAL ANALYSIS 
were administered IP at days - 4  and - 1. At day 0, peri­
toneal lavage was performed with 4 mL of PBS that con- Comparisons were only made between treatment groups 
tained 0.38% citrate. Quantification of cells was per- and their specific control groups. Statistical analysis of bio-
formed as described previously.
EXPERIMENTAL DESIGN
Three series of experiments were performed to assess the 
effects of macrophage elimination in the various tissues. 
Within each series, 3 groups of mice were used: a control 
group that received only zymosan and 2 experimental groups 
that received the Cl2MBP-containing liposome suspen­
sion either before or after administration of zymosan.
Thus, 3 groups of 15 animals were used to study the 
effects of IV liposome administration. The experimental
logical parameters (body temperature and body weight) was 
performed using the distribution-free curve analysis ac­
cording to Koziol et al.29 Since the zymosan-induced ill­
ness is characterized by distinct phases, comparisons were 
made separately for the course of the biological param­
eters in die acute phase (days 0-4) and late phase (days 8-12) 
of the model. The nonparametric Kruskal-Wallis and Wil- 
coxon 2-sample tests were used for statistical analysis of 
the ROWs. Noncontinuous data (mortality rates) were ana­
lyzed by use of the Fisher exact or x 2 tests, when appro­
priate. Differences between groups were considered to be 
statistically significant at P<.05.
IV with CliMBP-containing liposomes. Reduction of al- lethargic and hypothermic, hyperventilated, and started
veolar and peritoneal macrophages was confirmed by to lose weight and hemorrhagic fluid from the nostrils an d
quantification of the macrophage cell concentration in conjunctivae again. The mortality of the control anim als
the alveolar and peritoneal lavage fluid, respectively. Mice varied among the 3 experiments, with overall survival rates
that were treated IT with Cl2MBP-containing liposomes of 47%, 75%, and 50% in the control mice w ith IV, IT, and
strated a mean macrophage concentration of 
6.4X 10’’ cells per milliliter, while control mice dis-
IP treatment, respectively (Figure 2 ). Inspection of the 
lungs of the mice that died in the late phase or that w ere 
played a concentration of 27.0XIO'5 cells per milliliter. killed at day 12 demonstrated extremely hyperemic lungs 
Intraperitoneal administration of Cl2MBP-containing li- with hemorrhagic spots and occasionally massive hem or- 
posomes achieved a mean macrophage concentration of rhagic infarction. The abdomen showed signs of an ex- 
2.4 X 10'’ cells per milliliter, while a concentration of tensive fibroplastic peritonitis with massive adhesions. The 
40.7X 101 cells per milliliter was found in the peritoneal ROWs of the lungs, liver, and spleen were dramatically
lavage fluid of the control mice.
Intraperitoneal administration of zymosan induced 
a typical triphasic illness in all control animals as de-
dynam
increased compared with the control values (F ig u re  3 ).
Elimination ofliver and splenic m acrophages by IV 
administration of Cl2MBP-containing liposom es before 
or after challenge with zymosan did no t induce signifi-
0-4), the animals became hypothermic, lethargic, and ano- cant changes in the subsequent course of body w eight
rectic; they hyperventilated, lost weight and hemor- and temperature (data not shown). No significant changes
rhagic fluid from the nostrils and conjunctivae, and had were observed in the mortality between the control an d
diarrhea. Thereafter, the condition of the surviving ani- Cl2MBP-containing liposome-treated groups: overall sur-
_  M  ^  „  «  M -  ■ —  J  * 1  * f l  •  ^  # * V  /  1
mals improved temporarily. However, after 8 days, the clini­
cal condition worsened progressively. In this late hypo
vival rates were 47% in the control mice and 60% ancl 
53% when mice were treated w ith liposom es before or
dynamic phase (days 8-1,2), the animals became more after zymosan challenge, respectively (Figure 2). In tra-
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due to the fact that the animals died in the early phase of
With
no reliable conclusions could be made with respect to or­
gan damage. In the animals that were treated with lipo-
somes alter zymosan vnge, no statistici
ROWs
S’«
r ■ -■ * ^
_ I_______k. ^ _____a. l_- . aa . . ~ -■ ^ i . .  d fcb Al ha a tea l_ . 4. ■ - __1 S I_K . a a Laa l i  bi I. J . I al a Al u  a . L bl l_ ■ _______.
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This study shows that elimination of Kupffer cells and 
splenic macrophages (portal macrophages), either before 
or after zymosan challenge, is associated with lower, al­
though not significantly, late deaths and significantly lower 
relative liver weights, indicating less liver damage. This is 
consistent with studies that have documented that exces-
sive Kupffer cell activation is associated 
in liver function.16 Concomitantly, relative
ter zymosan chi
plained in view of other studies that have 
that ARDS and MODS 
Kupffer cells, which spill over endotoxin to 
induce an excessive activation of alveolar macr
Figure 1. Acid phosphatase activity of macrophages in mouse splenic 
tissue sections 48 hours after intravenous administration of liposomes that 
contained dichloromethylene biphosphonate. Top, Section of normal 
mouse spleen (original magnification x80). Bottom, Section of mouse 
spleen treated with liposomes that contained dichloromethylene 
biphosphonate. Most macrophages are eliminated; only some 
macrophages in the white pulp remained (original magnification x 100).
L'causevenous administration ofliposomes after zymosan chal­
lenge led to significantly increased relative lung weights, 
while relative liver weights were significantly reduced in 
both groups that were tested with liposomes (Figure 3). 
No significant differences were noticed in relative spleen 
and kidney weights.
Intratracheal administration ofliposomes that con­
tained C12MBP before or after zymosan challenge did not 
result in significant differences in the course of the bio­
logical parameters (data not shown). While 25% of the 
animals died in the control group, no deaths occurred
in the group that received liposomes before zymosan rimental in models or clinical situations that depend on
this phenomenon has been coined the “liver-lung axis.” 
Indeed, alveolar macrophages are releasing much more 
TNF in response to lipopolysaccharicle than Kupffer cells.50 
Thus, by this mechanism, elimination of portal macro­
phages could lead to an activation of alveolar macro­
phages that results in increased lung damage.
Our data did not show adverse effects on the mor­
tality rate by eliminating portal macrophages. This is in 
contrast with a study in the cecal ligation and puncture 
model, in which Kupffer cell blockade was achieved with 
gadolinium chloride.31 While increasing systemic immu­
nity, this method of macrophage blockade increased the 
mortality rate. These discordant results could be ex-
inium
blocks phagocytic activity of Kupffer cells, leaving mac­
rophage secretory activity relatively intact.52 The method,
we
cells, leaving no function intact.n Furthermore, while the 
zymosan-incluced generalized inflammation (ZIGI) model 
is largely independent of bacteria, the cecal ligation and
puncture
in which an intact host defense against bacteria is prob­
ably important.24,34 Apparently, the effects of manipulat­
ing macr
(P=.04), but elimination of alveolar macrophages after 
zymosan challenge did not significantly reduce the mor­
tality rate (Figure 2). Organ damage, as measured by the 
ROWs, was not significantly changed by elimination of 
alveolar macrophages (Figure 3).
Intraperitoneal administration of liposomes that con­
tained C12MBP did not significantly change the course of phages is essential for the host defense against intruding
the intact phagocytic activity of the host defense.
In this respect, our data of elimination of peritoneal 
macrophages are illustrative. Elimination of peritoneal mac­
rophages before zymosan challenge induced a dramatic in-
arlycrease m rate, suggesting that m
phase of this model, the function of peritoneal macro­
body weight and temperature (data not shown). How­
ever, administration of Cl2MBP-containing liposomes be­
fore zymosan challenge induced a dramatic mortality rate. 
While mortality was approximately 50% in the control 
group and the group that received liposomes after zymo­
san, it reached 90% if animals were pretreated with lipo­
somes (Figure 2; P=.02). The latter mortality was mainly
microorganisms or injurious agents like zymosan. How­
ever, elimination of peritoneal macrophages after zymo­
san challenge did not induce such effects since the mor­
tality rate and ROWs were not significantly different. So, 
there appears to be a differential involvement of perito­
neal macrophages in the development of MODS in t his 
model: a protective role in the early phase and an indif-
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Figure 2. Effects of intravenous (IV), intratracheal (IT), and intraperitoneal 
(IP) dichloromethylene biphosphonate-containing liposomes on survival 
rates. Solid circles indicate control mice; open circles, mice treated with 
liposomes that contained dichloromethylene biphosphonate before 
zymosan challenge; and open triangles, mice treated with liposomes that 
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Figure 3, Relative organ weights (ROWs) at 12 days after injection of 
zymosan. White bars indicate healthy animals; gray bars, zymosan-treated 
control mice; light blue bars, mice treated with liposomes that contained 
dichloromethylene biphosphonate before zymosan challenge; dark blue 
bars, mice treated with liposomes that contained dichloromethylene 
biphosphonate after zymosan challenge (data are expressed as 
mean±SEM, Wilcoxon 2-sample test; P- .01 [asterisks]); IV, intravenous; 
IT, intratracheal; and IP, intraperitoneal.
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nation of alveolar macrophages before zymosan chal­
lenge completely prevented mortality. This observation was 
consistently found in several pilot experiments (data not 
shown). This is in line with clinical data that have shown 
elevated levels of macrophage-derived cytokines (eg, TNF 
and interleukin-1) in bronchoalveolar lavage fluids in criti­
cally ill patients in whom ARDS develops.15 However, late 
elimination of alveolar macrophages did not alter the clini­
cal course or mortality rate, nor did it influence organ dam­
age. Thus, it appears that early alveolar activation is asso­
ciated w ith  m ortality, while MODS appears to be 
independent of late alveolar macrophage activation. Other 
investigators, however, have shown experimentally that 
lung injury in the cecal ligation and puncture model was 
associated with a gradual increase in alveolar macro­
phage activation.14 Evidence for a less important role of 
the activated alveolar macrophage in the evolution of ARDS 
is supported by the clinical observation that early ARDS 
was associated with an increased num ber of m acro­
phages, while a sustained elevated number of macro­
phages correlated with a decreased risk of death.38 These 
data suggest that early alveolar macrophage activation is 
associated with the onset of ARDS, while late alveolar mac­
rophage activation is associated with a resolution of ARDS.
A major finding of this study was that selective elimi­
nation of any macrophage subpopulation, either before or 
after zymosan challenge, could not prevent both organ dam­
age and death in this model. This could be explained by 
several hypotheses. First, during the development of MODS 
in this model, repopulation of some macrophages could al­
ready have been achieved in the late phase. Repopulation 
from the bone marrow requires 7 days for Kupffer cells and, 
depending on the type of macrophage, 7 days (red pulp mac­
rophages) to 60 days (marginal zone macrophages) for 
splenic macrophages.22 Alveolar macrophage repopula­
tion starts after 5 days and is complete after 18 days.27 Re­
population of peritoneal macrophages takes 7 days, and re­
population of macrophages of the omentum takes 7 to 28 
days.28 When those macrophages were eliminated before 
zymosan challenge, their reappearance would be almost 
complete in the late phase, while it would be only partial 
when those macrophages were eliminated after the zymo­
san challenge.22 Hence, the reappearance of those macro­
phages in this phase could trigger the development of MODS 
if the agents or events that keep the macrophages acti­
vated are still present. Second, there are also indications 
in other models that the nondepleted macrophages dem­
onstrate an increased activity.22 Thus, the elimination of 1 
subpopulation of macrophages could result in a compen­
satory activation of other macrophages or cell popula­
tions with an enhancement of the inflammatory response. 
In this respect, the observed increased lung organ damage 
after elimination of portal macrophages is an interesting 
phenomenon. Furthermore, elimination of peritoneal and 
alveolar macrophage populations was not complete; thus, 
the remaining macrophages could have hypothetically in­
duced MODS in this model. On the other hand, the dra­
matic effects of intra-alveolar and IP liposomes before zy­
mosan challenge suggest a significant contribution of the 
depletion of those macrophages to these phenomena.
The results could also be interpreted to support the 
notion that macrophage activation is not an important
feature in the development of MODS. Indeed, the m ac­
rophage hypothesis has been questioned because of re­
cent clinical data, indicating that preventive enhance­
m ent of m acro p h ag e  ac tiv ity  by  p o ly g lu c o tr io s y l 
glucopyranose glucan is beneficial for patients w ho are 
undergoing major surgery or m ultiple traum a .39,40 O n the 
other hand, our data indicate that elim ination of Kupffer 
cells and splenic m acrophages attenuates liver damage. 
Furthermore, elim ination of alveolar m acrophages be­
fore zymosan challenge could  fully prevent zym osan- 
induced death, indicating an im portant role for these m ac­
rophages in  the developm ent of MODS.
Our data further show that the elimination of certain
macrophage subpopulations and the elimination on spe-
lations, either protective or detrimental, in the development 
of MODS. Peritoneal macrophages appear to be im por­
tant in the host-defense mechanisms in the early phase, 
while contributing to the development of MODS in the late 
phase of this model. Kupffer cells and splenic m acro ­
phages appear to play an important pathophysiological role 
in all phases, while alveolar macrophages appear to be det­
rimental in the early phase. Thus, it remains to be deter­
mined which specific m acrophage functions or popu la­
tions are essential and need to be stimulated, and w hich 
are detrimental and need to be inhibited.
The ClzMBP used in this study was provided by Boeh- 
ringer Mannheim GmbH, Mannheim, Germany.
Corresponding author: Grard A. P. Nieuwenhuijzen, 
MD, Department of Surgery, St Elisabeth Hospital, Hil- 
varenbeekseweg 60, PO Box 90151, 5000 Tilburg, the Neth­
erlands.
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I
he MODS that progresses to multiple-organ failure is a serious problem for patients who undergo surgical proce­
dures. Once multiple-organ failure develops, the mortality rate is high. Thus, information about the factors that are 
involved in producing this problem will eventually be beneficial for our patients. In this issue of the ARCHIVES, 
Nieuwenhuijzen and coworkers provide important information about macrophage activity in various organs (eg, the liver 
and spleen, the lungs [alveolar macrophages], and peritoneal cavity). Macrophages in these organs or locations were de­
stroyed by liposomes that contained a toxic agent, Then, the experimental animals were challenged by IP zymosan, which is 
an agent that produces a severe inflammatory reaction. Goris and colleagues1,1 have previously shown that zymosan-induced 
inflammation produces MODS or multiple-organ failure.
In the present study, elimination of alveolar macrophages prevented deaths caused by peritoneal inflammation, whereas 
elimination of peritoneal macrophages increased the zymosan-associated mortality rate. The elimination of Kupffer cells (from 
the liver) and splenic macrophages decreased liver damage, but increased lung damage. Thus, with zymosan-induced peri­
toneal inflammation, peritoneal macrophages are protective, whereas alveolar macrophages are deleterious. There were also 
time differences of early and late effects.
Thus, what is the message for all of us who take care of patients who undergo surgical procedures? The most important 
message is that the host-defense systems are complex, and they can be protective in some circumstances while deleterious in 
others. There will not be simple solutions to such problems clinically. It is unlikely that there will be a magic bullet. All 
so-called magic bullets that have been subjected to randomized, prospective clinical trials have failed to reduce the mortality 
rate in patients. These agents include interleukin-1 receptor antagonist antiendotoxins, anti-INF antibodies, soluble TNF 
receptors, anti-platelet activating factor, and other agents. Thus, we must strive to prevent MODS 
ure by excellent patient care—operations without complications, minimal surgical procedures when possible, and maxi 
mum organ support. The more we learn from studies such as the one by Nieuwenhuijzen and coworkers and those 
et al1,2 commented on here, the more likely it is that we will be able to do something about overwhelming inflammation. 
Inflammation is necessary to heal wounds, control infection, and promote survival. Also, as Goris et al1,2 have described 
previously, overwhelming inflammation in patients is deleterious. The final question is: Can we fool Mother Nature and 
modulate a necessary but excessive response, namely, inflammation?
Arthur E  Baue, MD 
St Louis, Mo
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